GlassScriptPhysician profile
Patrick R Mcintyre
NPI 1407594369
$3,282.83
in general payments reported to CMS, 2019-2025
22 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $217 · 2024: $1,745 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298 · Travel and Lodging: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.82 |
| Travel and Lodging | $861.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,239.84 | 2024 | Axonics |
| Boston Scientific Corporation | $494.03 | 2024-2025 | Infinion 16, General - Therapies, Intracept |
| Sumitomo Pharma America, INC. | $364.60 | 2024-2025 | Orgovyx, Gemtesa |
| Abbott Laboratories | $246.64 | 2023-2025 | Eterna, Proclaim, Prodigy |
| Astellas Pharma US INC | $140.26 | 2024-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $98.07 | 2024-2025 | |
| Abbvie INC. | $95.67 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.36 | 2022-2023 | Relistor |
| Pfizer INC. | $72.60 | 2025 | |
| Tolmar, INC. | $60.16 | 2025 | Jatenzo, Eligard |
| Collegium Pharmaceutical, INC. | $57.67 | 2022-2023 | Xtampza |
| 180 Medical, INC. | $54.09 | 2025 | Gentlecath Glide |
| Janssen Biotech, INC. | $53.87 | 2024-2025 | Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $53.10 | 2024-2025 | |
| Endo USA, INC. | $37.66 | 2024-2025 | Xiaflex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $20.87 | 2025 | |
| Novo Nordisk INC | $20.81 | 2023 | Wegovy |
| Redhill Biopharma INC. | $19.03 | 2022 | |
| Progenics Pharmaceuticals, INC. | $18.43 | 2025 | |
| Scilex Pharmaceuticals INC. | $18.20 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.01 | 2022 | |
| Ethicon US, LLC | $15.86 | 2025 | Echelon Flex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.